fig3

Figure 3. Overall survival of chemorefractory aBTC. Figure 3 shows overall survival (OS) of chemorefractory aBTCs from pooled analysis of ABCs studies and second line clinical trials. ABCs studies include ABC-01, -02 and -03 clinical trials which explored the role of first-line systemic chemotherapy in advanced BTCs [cisplatin and gemcitabine vs. gemcitabine (ABC-01 and ABC-02) and cisplatin-gemcitabine-cediranib vs. cisplatin-gemcitabine-placebo (ABC-03)]. ASC: Active symptom control; PBO: placebo; FGF: fibroblast growth factor; FGFR: fibroblast growth factor receptor; IDH-1: isocitrate dehydrogenase 1; CCA: cholangiocarcinoma; BTCs: biliary tract cancers; aBTCs: advanced biliary tract cancers; 5FU/LV: 5-fluorouracil plus leucovorin; nal-IRI: fluorouracil and liposomial irinotecan; mFOLFOX: 5-fluorouracil plus oxaliplatin.